SCHEMBL978065

SCHEMBL978065

Nc1nnc(-c2sc3ccccc3c2Cl)c(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.48
MAOA P21397 1/20 0.48
MAPK1 P28482 1/20 0.48
ADRA1A P35348 1/20 0.48
SCN4A P35499 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
PDE3A Q14432 1/20 0.48
SCN5A Q14524 1/20 0.48
SCN9A Q15858 1/20 0.48
SCN2A Q99250 1/20 0.48
SCN3A Q9NY46 1/20 0.48
SCN10A Q9Y5Y9 1/20 0.48
CSNK1A1 P48729 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
LOXL2 Q9Y4K0 1/20 0.42
HPGD P15428 5/20 0.42
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23931345 0.79 SCN2A (0.41) CYP2D6SCN2ALOXL2HPGDALDH1A1
SCHEMBL23931343 0.77 DHFR (0.44) LOXL2HPGDALDH1A1MEN1KMT2A
SCHEMBL980491 0.72 CYP2D6 (0.45) CYP2D6MAOAMAPK1ADRA1ASCN4A
SCHEMBL15931657 0.71 MAPT (0.41) MAPK1PMP22LOXL2HPGDALDH1A1
SCHEMBL30413445 0.69 CSNK1A1 (0.55) CYP2D6MAOAMAPK1ADRA1ASCN4A
SCHEMBL979602 0.69 CSNK1A1 (0.55) CYP2D6MAOAMAPK1ADRA1ASCN4A
SCHEMBL978238 0.69 APP (0.50) CYP2D6MAOAMAPK1ADRA1ASCN4A
SCHEMBL7666598 0.68 MCL1 (0.52) BLMLOXL2HPGDALDH1A1MEN1
SCHEMBL10811842 0.67 SCN9A (0.75) CYP2D6MAOAMAPK1ADRA1ASCN4A
SCHEMBL14315167 0.67 LOXL2 (0.59) LOXL2HPGDALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165869-A1 DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME UNIVERSITY OF GREENWICH (GB) 2023-06-01 US claimed
EP-3002280-B1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIV GREENWICH (GB) 2023-05-24 EP claimed
EP-4138838-A1 INTERLEUKIN INHIBITORS University of Greenwich (GB) 2023-03-01 EP claimed
EP-4138839-A1 DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME University of Greenwich (GB) 2023-03-01 EP claimed
WO-2021214495-A1 DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME UNIVERSITY OF GREENWICH (GB) 2021-10-28 WO claimed
WO-2021214494-A1 INTERLEUKIN INHIBITORS UNIVERSITY OF GREENWICH (GB) 2021-10-28 WO claimed
US-9422253-B2 Cyclic triazo and diazo sodium channel blockers UNIVERSITY OF GREENWICH (GB) 2016-08-23 US claimed
US-20140155403-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2014-06-05 US claimed
EP-3002280-B1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIV GREENWICH (GB) 2023-05-24 EP disclosed
EP-4138838-A1 INTERLEUKIN INHIBITORS University of Greenwich (GB) 2023-03-01 EP disclosed
EP-4138839-A1 DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME University of Greenwich (GB) 2023-03-01 EP disclosed
WO-2021214495-A1 DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME UNIVERSITY OF GREENWICH (GB) 2021-10-28 WO disclosed
WO-2021214494-A1 INTERLEUKIN INHIBITORS UNIVERSITY OF GREENWICH (GB) 2021-10-28 WO disclosed
US-9862691-B2 Cyclic triazo and diazo sodium channel blockers UNIVERSITY OF GREENWICH (GB) 2018-01-09 US disclosed
US-9422253-B2 Cyclic triazo and diazo sodium channel blockers UNIVERSITY OF GREENWICH (GB) 2016-08-23 US disclosed
EP-3002280-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS University of Greenwich (GB) 2016-04-06 EP disclosed
US-20140155403-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2014-06-05 US disclosed
US-20110009413-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2011-01-13 US disclosed
EP-2229371-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS University of Greenwich (GB) 2010-09-22 EP disclosed
WO-2009090431-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS UNIVERSITY OF GREENWICH (GB) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155403-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS SCN1A, SCN1B, SCN3A CYP2D6 1326/4885MAOA 321/4885MAPK1 3993/4885
US-20110009413-A1 CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS CACNA1E, SCN2B, SCN3A CYP2D6 3472/4885MAOA 460/4885MAPK1 2697/4885
US-20230165869-A1 DIAZINE AND TRIAZINE COMPOUNDS TO TREAT CYTOKINE STORM SYNDROME IFNG, TNF, IL1A CYP2D6 2190/4885MAOA 3195/4885MAPK1 1954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.